PL353854A1 - Podstawione pochodne 1,5-dihydropirol-2-onu, skutePodstawione pochodne 1,5-dihydropirol-2-onu, skuteczne jako substancje antagonistyczne wobec receptoczne jako substancje antagonistyczne wobec receptora-NMDA w leczeniu stanów bólowychra-NMDA w leczeniu stanów bólowych - Google Patents

Podstawione pochodne 1,5-dihydropirol-2-onu, skutePodstawione pochodne 1,5-dihydropirol-2-onu, skuteczne jako substancje antagonistyczne wobec receptoczne jako substancje antagonistyczne wobec receptora-NMDA w leczeniu stanów bólowychra-NMDA w leczeniu stanów bólowych

Info

Publication number
PL353854A1
PL353854A1 PL00353854A PL35385400A PL353854A1 PL 353854 A1 PL353854 A1 PL 353854A1 PL 00353854 A PL00353854 A PL 00353854A PL 35385400 A PL35385400 A PL 35385400A PL 353854 A1 PL353854 A1 PL 353854A1
Authority
PL
Poland
Prior art keywords
dihydropyrrol
pain
derivatives
substituted
treatment
Prior art date
Application number
PL00353854A
Other languages
English (en)
Inventor
MichaelPrzewosny Michael Przewosny
Hans-DietrichStachel Hans-Dietrich Stachel
HermannPoschen-Rieder Hermann Poschen-Rieder
Original Assignee
Grunenthal Gmbhgrunenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grunenthal Gmbhgrunenthal Gmbh filed Critical Grunenthal Gmbhgrunenthal Gmbh
Publication of PL353854A1 publication Critical patent/PL353854A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
PL00353854A 1999-08-06 2000-07-25 Podstawione pochodne 1,5-dihydropirol-2-onu, skutePodstawione pochodne 1,5-dihydropirol-2-onu, skuteczne jako substancje antagonistyczne wobec receptoczne jako substancje antagonistyczne wobec receptora-NMDA w leczeniu stanów bólowychra-NMDA w leczeniu stanów bólowych PL353854A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19936719A DE19936719A1 (de) 1999-08-06 1999-08-06 Substituierte 1,5-Dihydropyrrol-2-on-Derivate
PCT/EP2000/007100 WO2001010833A1 (de) 1999-08-06 2000-07-25 Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen

Publications (1)

Publication Number Publication Date
PL353854A1 true PL353854A1 (pl) 2003-12-01

Family

ID=7917172

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00353854A PL353854A1 (pl) 1999-08-06 2000-07-25 Podstawione pochodne 1,5-dihydropirol-2-onu, skutePodstawione pochodne 1,5-dihydropirol-2-onu, skuteczne jako substancje antagonistyczne wobec receptoczne jako substancje antagonistyczne wobec receptora-NMDA w leczeniu stanów bólowychra-NMDA w leczeniu stanów bólowych

Country Status (25)

Country Link
US (1) US6642267B2 (pl)
EP (1) EP1200402B1 (pl)
JP (1) JP2003506437A (pl)
KR (1) KR20020025214A (pl)
CN (1) CN1378532A (pl)
AR (1) AR028848A1 (pl)
AT (1) ATE304530T1 (pl)
AU (1) AU782435B2 (pl)
BR (1) BR0013311A (pl)
CA (1) CA2381033A1 (pl)
CO (1) CO5200758A1 (pl)
CZ (1) CZ2002441A3 (pl)
DE (2) DE19936719A1 (pl)
ES (1) ES2248104T3 (pl)
HK (1) HK1046405A1 (pl)
HU (1) HUP0201937A3 (pl)
IL (1) IL147977A0 (pl)
MX (1) MXPA02001212A (pl)
NO (1) NO20020574L (pl)
NZ (1) NZ516988A (pl)
PE (1) PE20010402A1 (pl)
PL (1) PL353854A1 (pl)
SK (1) SK1702002A3 (pl)
WO (1) WO2001010833A1 (pl)
ZA (1) ZA200201788B (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
EP2425846A1 (en) * 2004-12-23 2012-03-07 Voyager Pharmaceutical Corporation Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease
CA2620374C (en) * 2005-09-28 2012-12-11 Thomas Meyer Pharmaceutical compositions for the treatment of inner ear disorders
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
KR20160127181A (ko) 2008-08-12 2016-11-02 진판델 파마슈티컬스 인코포레이티드 질환 위험 인자의 식별 방법
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
CN107362165A (zh) 2011-01-10 2017-11-21 金帆德尔制药股份有限公司 用于治疗阿尔茨海默病的方法和药物产品
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
KR102084185B1 (ko) * 2013-08-29 2020-03-04 주식회사 대웅제약 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법
US10708389B2 (en) * 2016-12-06 2020-07-07 Intelligrated Headquarters, Llc Phased deployment of scalable real time web applications for material handling system
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
WO2025145182A1 (en) * 2023-12-29 2025-07-03 Case Western Reserve University Selective inhibitors of t cell activation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL258360A (pl) * 1960-11-25
DE3434562A1 (de) * 1984-09-20 1986-03-27 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von pyrrothinderivaten
GB2170498A (en) * 1985-02-04 1986-08-06 Ici Plc Processes for making fungicidal dithiolopyrrolones
GB2173499A (en) * 1985-02-04 1986-10-15 Ici Plc Fungicidal dithiolopyrrolones
GB9210393D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
AU782435B2 (en) 2005-07-28
HUP0201937A2 (en) 2002-10-28
DE50011178D1 (de) 2005-10-20
EP1200402A1 (de) 2002-05-02
HUP0201937A3 (en) 2002-12-28
ZA200201788B (en) 2003-08-27
ES2248104T3 (es) 2006-03-16
CO5200758A1 (es) 2002-09-27
US6642267B2 (en) 2003-11-04
AR028848A1 (es) 2003-05-28
NO20020574L (no) 2002-03-25
DE19936719A1 (de) 2001-02-15
AU6827900A (en) 2001-03-05
CZ2002441A3 (cs) 2002-05-15
BR0013311A (pt) 2003-01-28
ATE304530T1 (de) 2005-09-15
CA2381033A1 (en) 2001-02-15
CN1378532A (zh) 2002-11-06
IL147977A0 (en) 2002-09-12
JP2003506437A (ja) 2003-02-18
US20020161033A1 (en) 2002-10-31
WO2001010833A1 (de) 2001-02-15
NO20020574D0 (no) 2002-02-05
KR20020025214A (ko) 2002-04-03
SK1702002A3 (en) 2002-07-02
NZ516988A (en) 2004-11-26
MXPA02001212A (es) 2002-07-02
EP1200402B1 (de) 2005-09-14
PE20010402A1 (es) 2001-05-05
HK1046405A1 (zh) 2003-01-10

Similar Documents

Publication Publication Date Title
IL147977A0 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
HUP0105079A3 (en) Indole derivatives and their use as mcp-1 antagonists, process for preparation of the compounds and medicaments containing them
MXPA03009644A (es) Grupos azabiciclicos sustituidos para el tratamiento de enfermedades.
GB9911053D0 (en) 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
PL363907A1 (pl) Skondensowane pochodne pirydyny do zastosowania jako antagoniści receptora waniloidowego do leczenia bólu
HUP0202253A3 (en) Selective iglur5 receptor antagonists for the treatment of migraine
ZA200110254B (en) Process for the preparation of herbicidal derivatives.
PL356990A1 (pl) Pochodne izoksazolokarboksyamidu
IL161157A0 (en) 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
WO2000012623A3 (en) Use of 5-th receptor antagonists for the treatment of parkinson's disease
HUP0202736A3 (en) Substituted aromatic-ring compounds, process for producing the same, and pharmaceutical compositions containing them and use thereof
AU5497000A (en) Non-malignant disease treatment with ras antagonists
IL147978A0 (en) Substituted pyrrolidin-2,3,4-trion-3-oxime derivatives useful as nmda-receptor antagonists
HUP0203611A3 (en) 14,15-beta-methylene substituted androgens and their use for preparation of the medicaments
PL350536A1 (en) Biphenyl derivatives as antagonists of the neurokinine-1 receptor
IL162188A0 (en) Process for the preparation of Ä1,4,5Ü-oxadiazepine derivatives
IL139023A0 (en) Process for the preparation of 2,3,5-trimethyl-p- benzoquinone
AU3476599A (en) Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression (5-ht1 receptor antagonists)
GB2363605B (en) Process for the preparation of alpha-aminoketone derivatives
PL377292A1 (pl) Ulepszony sposób wytwarzania 1,3-podstawionych indenów
SI1200402T1 (sl) Substituirani 1,5-dihidropirol-2-on-derivati, ucinkoviti kot antagonisti NMDA-receptorja za tretiranje bolecinskih stanj
HUP9902737A3 (en) The use of aryl-cyclohexylamine derivatives for preparing pharmaceutical compositions suitable for treatment of cns disorders
HUP0000982A2 (en) Process for the preparation of 1,1-dioxo-penicillanic acid derivatives
AU6523200A (en) Vitronectin receptor antagonists useful for the treatment of strokes
ITMI992457A0 (it) Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidrois ochinolin-3-carbossiammide

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)